← Search & browse all drugs

encephalitis, Japanese, live attenuated

J07BA03

Forms & Strengths

Lyophilized live attenuated Japanese encephalitis vaccine
Single-dose vial with accompanying diluent for reconstitution

Adult Dosing

Primary series: 0.5 mL subcutaneous injection
Booster dose: 0.5 mL subcutaneous injection 1 to 2 years after primary dose if ongoing exposure risk persists

Pediatric Dosing

Children 9 months to 18 years: 0.5 mL subcutaneous injection
Consult specific regional guidelines for exact age lower limits and booster recommendations in endemic areas

Indications

Active immunization for the prevention of Japanese encephalitis
Indicated for travelers spending 1 month or more in endemic areas during transmission season
Indicated for expatriates and long-term travelers living in areas with risk of Japanese encephalitis

Mechanism of Action

Induces the production of neutralizing antibodies against the Japanese encephalitis virus
Provides active immunity and immune memory mimicking natural infection without causing disease

Contraindications

Hypersensitivity to any component of the vaccine, including gelatin or kanamycin
Severe allergic reaction (e.g., anaphylaxis) after a previous dose of Japanese encephalitis vaccine
Congenital or acquired immune deficiency, including symptomatic HIV infection
Pregnancy and lactation

Adverse Reactions

Injection site pain, tenderness, redness, and swelling
Fever, headache, myalgia, and fatigue
Systemic allergic reactions including rash and urticaria
Rare cases of severe hypersensitivity or anaphylaxis

Drug Interactions

Immunosuppressive therapies and corticosteroids may reduce the immune response to the live vaccine
Can be administered simultaneously with other live or inactivated vaccines using separate syringes and injection sites
Avoid administration within 3 months of receiving blood products containing antibodies to prevent interference with viral replication

Curated Content: Needs Vetting Before Put to Clinical Use